TVTX · Travere Therapeutics, Inc.

Track TVTX — free Ask ALVIS about TVTX

$55.92 -0.76 (-1.34%) At close · Jul 28

Market Cap

$5.27B

92.99M

Up next

Next earnings call

Aug 4, 2026 Scheduled · in 1 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 4, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Ask ALVIS about this →

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Buy Momentum Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Very High

Market backdrop VIX 18.2 · elevated Equity put/call 0.66

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +51%

above

Price vs 50-day avg +9%

above

RSI (14) 57

neutral

MACD trend Negative

52-week position 92%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Strong

1-month return −4%

trailing

6-month return +82%

trailing

YTD return +48%

this year

Relative strength +76%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $52 › 200d $38 — 50d above 200d

Institutional flow Accumulating

40 of 263 funds reported for Jun 30 · net +740.9K sh shares · +13 new

Insider flow Distributing

Net -$4.6M over 90 days · 100% sells

Short interest Falling

12.92% of float · ▼ -5.3% MoM · 9.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

263 holders — mid 3-yr range

Squeeze score 91

high risk · 0–100

Fundamentals

Excellent

EPS growth +93%

Y/Y

Free cash flow $37.1M

Balance sheet $93.0M

net cash

Quant / Vol

risk profile

Very High

Volatility 71%

annualized · 1-yr

Max drawdown −33%

past year

ATR 4.4%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy

1 · 3 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+51% Bullish

Price vs 50-day avg

+9% Bullish

RSI (14)

57 Neutral

MACD trend

Negative Bearish

52-week position

92% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $52 › 200d $38 — 50d above 200d

Institutional flow Accumulating

40 of 263 funds reported for Jun 30 · net +740.9K sh shares · +13 new

Insider flow Distributing

Net -$4.6M over 90 days · 100% sells

Short interest Falling

12.92% of float · ▼ -5.3% MoM · 9.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

263 holders — mid 3-yr range

Price context

position in its 52-week range

52-wk low $15 Now $57 · 92% 52-wk high $60

vs 200-day avg +51% vs 50-day avg +9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
new patient start forms (PSFs)	993	first quarter 2026	—

Non-GAAP adjusted net income non-GAAP	$4.1M	the first quarter of 2026	—
Non-GAAP adjusted R&D expenses non-GAAP	$51.5M	the first quarter of 2026	—
Non-GAAP adjusted SG&A expenses non-GAAP	$69.3M	the first quarter of 2026	—
U.S. net product sales of FILSPARI	$105.2M	the first quarter of 2026	+88.3%

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
TVTX Travere Therapeutics, Inc. this stock	$5.27B	+48.3%	+32.7%	—	12.9%
ONC BeOne Medicines Ltd.	$471.01B	+7.3%	+22179.2%	958.5	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$121.57B	+5.7%	+46.2%	28.4	2.0%
REGN Regeneron Pharmaceuticals, Inc.	$69.95B	-13.5%	+20.8%	16.3	3.3%
ARGX Argenx SE	$55.61B	+5.7%	—	—	2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

273

% held: 112.8%
Reported: 40 of 263
Top holder: JANUS HENDERSON GROUP PLC

Held Float

View

Held by Funds

Fund positions

299

View

Short & Settlement

Short Interest Falling

Shares short

12.0M

Days to cover: 9.2d
Change: -672.2K sh

View

Short Volume

Short vol %

70%

As of: Jul 28, 2026

Short Total

View

Fails to Deliver

FTD shares

89.5K

Value: $5.2M
As of: Jun 30, 2026

View

Off-Exchange

Off-exchange %

67.6%

Week of: May 4, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$4.6M

Buyers / Sellers: 0 / 9

Buyers Sellers

View

Financials

Revenue (FY)

$490.7M

Net income (FY): $-25.5M
EPS diluted: $-0.29

View

Filings

SEC Filings

Latest

8-K

Filed: Jul 9, 2026
This year: 15

View

Proposed Sales

Value

$500.4K

Shares: 10.0K
Filed: Jun 12, 2026

View

Earnings & Events

Earnings Calls Upcoming

Next call

Aug 4, 2026

Last call: Jun 8, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
TVTX	-0.1%	-4.0%	+82.3%	-0.2%	+48.3%
SPY	-0.6%	+0.7%	+6.8%	-1.0%	+8.4%
vs SPY	+0.5%	-4.6%	+75.5%	+0.8%	+40.0%

Key facts CIK 1438533 CUSIP 89422G107 13F (30d) 37 filings 37 filers Visit website Investor relations

TVTX · Travere Therapeutics, Inc.

Price & Indicators

Up next

AI Brief

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance